Long-Acting Growth Hormone (LAGH)

ISSN 1662-4009 (online)

An indispensable reference tool endorsed by the European Society for Paediatric Endocrinology

Previous issue | Volume 20 | ESPEYB20 | Next issue

Yearbook of Paediatric Endocrinology 2023

2. Growth and Growth Factors

Previous section
Important for Clinical Practice

Table of contents

Next section
New Perspectives

ey0020.2-7 | Long-Acting Growth Hormone (LAGH)

2.7. Weekly somapacitan is effective and well tolerated in children with GH deficiency: The randomized phase 3 REAL4 trial

ey0020.2-8 | Long-Acting Growth Hormone (LAGH)

2.8. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: A phase 3 study

ey0020.2-9 | Long-Acting Growth Hormone (LAGH)

2.9. Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results

ey0020.2-10 | Long-Acting Growth Hormone (LAGH)

2.10. Long-acting PEGylated growth hormone in children with idiopathic short stature

ey0020.2-11 | Long-Acting Growth Hormone (LAGH)

2.11. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study

ESPE Yearbook of Paediatric Endocrinology
ISSN 1662-4009 (Online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more

ESPE Yearbook of Paediatric Endocrinology